{"id":36483,"date":"2018-05-29T15:40:00","date_gmt":"2018-05-29T13:40:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/"},"modified":"2024-07-29T08:02:55","modified_gmt":"2024-07-29T06:02:55","slug":"ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/","title":{"rendered":"Ipsen annonce la pr\u00e9sentation de donn\u00e9es cliniques lors de l\u2019ASCO, t\u00e9moignant de son engagement aupr\u00e8s des patients atteints de cancer"},"content":{"rendered":"<p> <\/p>\n<p><b>Paris (France), le 29 mai 2017 \u2013<\/b>\u00a0Ipsen (Euronext : IPN ; ADR : IPSEY) a annonc\u00e9 aujourd\u2019hui que<br \/>le cabozantinib (Cabometyx\u00ae) et l\u2019irinot\u00e9can liposomal pour injection (Onivyde\u00ae) feront l\u2019objet de<br \/>8 pr\u00e9sentations lors de r\u00e9union annuelle 2018 de l\u2019American Society of Clinical Oncology (ASCO).<br \/>Cette r\u00e9union annuelle se tiendra du 1er au 5 juin 2018 \u00e0 Chicago (Illinois, \u00c9tats-Unis).<br \/>Alexandre Lebeaut, Vice-Pr\u00e9sident Ex\u00e9cutif, R&amp;D et Chief Scientific Officer, Ipsen a d\u00e9clar\u00e9 :<\/p>\n<blockquote>\n<p>\u00ab\u00a0Les produits d\u2019Ipsen en oncologie, et notamment Onivyde, D\u00e9capeptyl\u00ae\u00a0et Cabometyx\u00ae, ont \u00e9t\u00e9 \u00e9valu\u00e9s par de nombreuses \u00e9quipes scientifiques dans le monde : soit directement par les investigateurs, soit par nos partenaires, soit par Ipsen. Les r\u00e9sultats de certaines de ces<br \/>investigations seront d\u00e9voil\u00e9s lors de sessions de pr\u00e9sentations orales des abstracts. Nous nous<br \/>engageons \u00e0 d\u00e9ployer tous nos efforts pour lutter contre le cancer, et \u00e0 travers nos \u00e9changes lors de l\u2019ASCO 2018 nous continuerons \u00e0 innover en oncologie, pour mieux soigner les patients.\u00a0\u00bb<\/p>\n<\/blockquote>\n<p><b>Le cabozantinib (Cabometyx\u00ae) fera l\u2019objet de 7 abstracts :<\/b><br \/><b>Le cabozantinib (Cabometyx\u00ae) fera l\u2019objet d\u2019une discussion, lors d\u2019une pr\u00e9sentation de poster\u00a0<\/b><b>orale :<\/b><\/p>\n<ul>\n<li style=\"margin-bottom:3px\">[Abstract 4019] Discussion autour du poster 208 : Dimanche 3 juin, 16h45 \u2013 18h00, Hall D2<br \/>o Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial<br \/>o Auteur : Ghassan Abou-Alfa [Sponsor : Exelixis]<br \/>Le cabozantinib (Cabometyx\u00ae) fera l\u2019objet d\u2019autres pr\u00e9sentations :<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\">[Abstract 4556] Poster 382 \u2013 Cat\u00e9gorie : Genitourinary (Nonprostate) Cancer ; Samedi 2 juin, 8h00 \u2013 11h30, Hall A<br \/>o Titre : Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203)<br \/>o Auteur : Ronald Chen [Sponsor : Ipsen]<\/li>\n<li style=\"margin-bottom:3px\">[Abstract 4598] Poster 418a \u2013 Cat\u00e9gorie : Genitourinary (Nonprostate) Cancer ; Samedi 2 juin, 8h00 \u2013 11h30, Hall A<br \/>o A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER)<br \/>o Auteur : Toni Choueiri [Sponsor : Bristol-Myers Squibb, Exelixis &amp; Ipsen]<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\">[Abstract 4601] Poster 419b \u2013 Cat\u00e9gorie : Genitourinary (Nonprostate) Cancer ; Samedi 2 juin, 8h00 \u2013 11h30, Hall A<br \/>o CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced\/metastatic renal cell carcinoma<br \/>o Auteur : Nizar Tannir [Sponsor : Calithera Biosciences, Inc]<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\">[Abstract 4088] Poster 277 \u2013 Cat\u00e9gorie : Gastrointestinal (Noncolorectal) Cancer ; Dimanche 3 juin, 8h00 \u2013 11h30, Hall A<br \/>o Outcomes based on receipt of sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)<br \/>o Auteur : Robin Kelley [Sponsor : Exelixis]<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\">[Abstract 4090] Poster 279 \u2013 Cat\u00e9gorie : Gastrointestinal (Noncolorectal) Cancer ; Dimanche 3 juin, 8h00 \u2013 11h30, Hall A<br \/>o Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)<br \/>o Auteur : Lorenza Rimassa [Sponsor : Exelixis]<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\">[Abstract TPS 4157] Poster 333a \u2013 Cat\u00e9gorie : Gastrointestinal (Noncolorectal) Cancer ; Dimanche 3 juin, 8h00 \u2013 11h30, Hall A<br \/>o A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-MET coexpressing metastatic pancreatic adenocarcinoma<br \/>o Auteur : Olumide Gbolahan [Sponsor : Exelixis]<\/li>\n<\/ul>\n<p><b>L\u2019 irinot\u00e9can liposomal \/ nal-IRI (ONIVYDE\u00ae) fera l\u2019objet d\u2019un poster :<\/b><\/p>\n<ul>\n<li style=\"margin-bottom:3px\">[Abstract 4111] Poster 300 \u2013 Cat\u00e9gorie : Gastrointestinal (Noncolorectal) Cancer ; Dimanche 3 juin, 8h00 \u2013 11h30, Hall A<br \/>o A phase 1\/2, open-label dose-escalation study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil\/leucovorin (5-FU\/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer (mPAC).<br \/>o Auteur : Andrew Dean [Sponsor : Ipsen]<\/li>\n<\/ul>\n<p><\/p>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1233,3556,3560],"tags":[],"class_list":["post-36483","press_release","type-press_release","status-publish","hentry","category-pressrelease-fr","category-corporate-pressrelease-fr","category-oncology-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ipsen annonce la pr\u00e9sentation de donn\u00e9es cliniques lors de l\u2019ASCO, t\u00e9moignant de son engagement aupr\u00e8s des patients atteints de cancer<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen annonce la pr\u00e9sentation de donn\u00e9es cliniques lors de l\u2019ASCO, t\u00e9moignant de son engagement aupr\u00e8s des patients atteints de cancer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-29T06:02:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/05e5e9dcc9e44c61de10732d1d0a1352\"},\"headline\":\"Ipsen annonce la pr\u00e9sentation de donn\u00e9es cliniques lors de l\u2019ASCO, t\u00e9moignant de son engagement aupr\u00e8s des patients atteints de cancer\",\"datePublished\":\"2018-05-29T13:40:00+00:00\",\"dateModified\":\"2024-07-29T06:02:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/\"},\"wordCount\":590,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"articleSection\":[\"Communiqu\u00e9 de presse\",\"Corporate\",\"Oncologie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/\",\"name\":\"Ipsen annonce la pr\u00e9sentation de donn\u00e9es cliniques lors de l\u2019ASCO, t\u00e9moignant de son engagement aupr\u00e8s des patients atteints de cancer\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2018-05-29T13:40:00+00:00\",\"dateModified\":\"2024-07-29T06:02:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen annonce la pr\u00e9sentation de donn\u00e9es cliniques lors de l\u2019ASCO, t\u00e9moignant de son engagement aupr\u00e8s des patients atteints de cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/05e5e9dcc9e44c61de10732d1d0a1352\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen annonce la pr\u00e9sentation de donn\u00e9es cliniques lors de l\u2019ASCO, t\u00e9moignant de son engagement aupr\u00e8s des patients atteints de cancer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen annonce la pr\u00e9sentation de donn\u00e9es cliniques lors de l\u2019ASCO, t\u00e9moignant de son engagement aupr\u00e8s des patients atteints de cancer","og_url":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/","og_site_name":"Global","article_modified_time":"2024-07-29T06:02:55+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/05e5e9dcc9e44c61de10732d1d0a1352"},"headline":"Ipsen annonce la pr\u00e9sentation de donn\u00e9es cliniques lors de l\u2019ASCO, t\u00e9moignant de son engagement aupr\u00e8s des patients atteints de cancer","datePublished":"2018-05-29T13:40:00+00:00","dateModified":"2024-07-29T06:02:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/"},"wordCount":590,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","articleSection":["Communiqu\u00e9 de presse","Corporate","Oncologie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/","url":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/","name":"Ipsen annonce la pr\u00e9sentation de donn\u00e9es cliniques lors de l\u2019ASCO, t\u00e9moignant de son engagement aupr\u00e8s des patients atteints de cancer","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2018-05-29T13:40:00+00:00","dateModified":"2024-07-29T06:02:55+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-annonce-la-presentation-de-donnees-cliniques-lors-de-lasco-temoignant-de-son-engagement-aupres-des-patients-atteints-de-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen annonce la pr\u00e9sentation de donn\u00e9es cliniques lors de l\u2019ASCO, t\u00e9moignant de son engagement aupr\u00e8s des patients atteints de cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/05e5e9dcc9e44c61de10732d1d0a1352","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b569564123e1c5c4bb45b008fc273d5bfdd6464d8a8497307ebbe91af50ed000?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":1,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36483\/revisions"}],"predecessor-version":[{"id":62846,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36483\/revisions\/62846"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=36483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=36483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=36483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}